Clinical Trial Update: Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ALKS 3831 for body weight effects in young adults recently diagnosed with schizophrenia, schizophreniform disorder, or bipolar I diso…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia
• Schizophreniform Disorders

Drugs mentioned

• ALKS 3831

Snippet

Sponsor: Alkermes, Inc. | Conditions: Schizophrenia, Schizophreniform Disorders | Phase 3 | Status: COMPLETED | Results posted: 2023-01-19